deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02337829

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

A Phase II Study Using ACP-196 (Acalabrutinib) in Patients With Relapsed/Refractory and Treatment-naïve Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Antitumor Response.

Sponsor: Acerta Pharma BV

Conditions Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
Interventions Acalabrutinib (Arm A) Acalabrutinib (Arm B)
Updated 28 times since 2017 Last updated: Dec 16, 2025 Started: Jan 12, 2015 Primary completion: Jun 26, 2020 Completion: Oct 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, this trial is completed. The trial is conducted by Acerta Pharma BV and has accumulated 28 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Oct 2019 · 7 months · monthly snapshot~Oct 2019 – ~Dec 2020 · 14 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Feb 2022 · 3 months · monthly snapshot~Feb 2022 – ~May 2022 · 3 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Aug 2023 · 4 months · monthly snapshot~Aug 2023 – ~Dec 2023 · 4 months · monthly snapshot~Dec 2023 – ~Mar 2024 · 3 months · monthly snapshot~Mar 2024 – ~Jun 2024 · 3 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Jun 2025 · 4 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

28 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Feb 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 23 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Mar 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Dec 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  7. Feb 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  8. Nov 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  9. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  10. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  11. Feb 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  12. Nov 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  13. Sep 2021 — Nov 2021 [monthly]

    Active Not Recruiting PHASE2

  14. Jun 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  15. Mar 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE2

  16. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  17. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  18. Oct 2019 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  19. Mar 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown Status → Active Not Recruiting

  20. Jan 2019 — Mar 2019 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  21. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE2

  22. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  23. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Acerta Pharma BV
  • National Institutes of Health (NIH)
Data source: Acerta Pharma BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations